SCHEMBL13825549

SCHEMBL13825549

CC(=O)Nc1cc(C(F)(F)F)c(N)cc1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.45
HSD17B10 Q99714 2/20 0.45
AKR1C3 P42330 3/20 0.42
AKR1C2 P52895 3/20 0.42
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
MPO P05164 1/20 0.40
GRIK1 P39086 1/20 0.39
CFTR P13569 2/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TAS2R14 Q9NYV8 2/20 0.37
PIK3CA P42336 1/20 0.37
RORC P51449 1/20 0.37
PTPN5 P54829 1/20 0.37
RXFP1 Q9HBX9 1/20 0.36
AR P10275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5165192 0.85 CFTR (0.52) KDM4EHSD17B10ALDH1A1HPGDHDAC1
SCHEMBL13500100 0.82 CFTR (0.48) KDM4EHSD17B10AKR1C3AKR1C2MPO
SCHEMBL27669616 0.78 KDM4E (0.42) KDM4EHSD17B10AKR1C3AKR1C2ALDH1A1
SCHEMBL15958948 0.78 KDM4E (0.42) KDM4EHSD17B10AKR1C3AKR1C2ALDH1A1
SCHEMBL5168011 0.77 ALDH1A1 (0.49) KDM4EHSD17B10AKR1C3AKR1C2ALDH1A1
SCHEMBL5181564 0.76 AKR1C3 (0.41) KDM4EHSD17B10AKR1C3AKR1C2ALDH1A1
SCHEMBL11841798 0.74 ALDH1A1 (0.47) KDM4EHSD17B10ALDH1A1HPGDCFTR
SCHEMBL31314547 0.73 KDM4E (0.50) KDM4EHSD17B10ALDH1A1HPGDCFTR
SCHEMBL23539879 0.72 KDM4E (0.46) KDM4EHSD17B10AKR1C3AKR1C2MPO
SCHEMBL20150027 0.72 KDM4E (0.46) KDM4EHSD17B10ALDH1A1HPGDCFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773788-B1 Quinazoline derivatives NOVARTIS AG (CH) 2012-11-14 EP disclosed